Advanced Therapy Medicinal Products Market | USD 171.37 Bn by 2034
The advanced therapy medicinal products market size was exhibited at USD 35.96 billion in 2024 and is projected to hit around USD 171.37 billion by 2034, growing at a CAGR of 16.9% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 42.04 Billion |
| Market Size by 2034 | USD 171.37 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 16.9% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Therapy Type, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG; UniQure N.V.; Celgene Corporation; Gilead Lifesciences, Inc.; Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; MEDIPOST; Vericel Corporation; PHARMICELL Co., Ltd; Organogenesis Inc. |
The emergence of Advanced Therapy Medicinal Products (ATMPs) has transformed the pharmaceutical industry and disease treatment landscape. It has opened new routes for the treatment of incurable diseases and several cancer types. The success of products such as Kymriah, Zolgensma, and others is the key factor driving the market. The COVID-19 pandemic has triggered the application of advanced therapies in virology research to a major extent. A study was issued in December 2020 which stated the potential of T-cell therapy for the treatment of high-risk COVID-19 infected individuals. Prior to this, in September 2020, the U.S. FDA approved the ALVR109 (an allogeneic T-cell therapy IND application) designed for the treatment of COVID-19 patients.
This is anticipated to drive investment in R&D of advanced therapy for SARS-CoV2 infections. Furthermore, a growing number of Mesenchymal Stromal/Stem Cells (MSCs) based clinical trials have been registered recently as a new treatment paradigm for SARS-CoV-2 infection. These therapies have shown promising results as the treatment modality in research programs, further supplementing the marketspace's organic revenue generation.
Although the market for advanced therapy medicinal products is currently in its nascent stage, it is continuously growing. Conventional drug manufacturers striving to gain a competitive edge are considering ATMPs as a lucrative source of revenue in future healthcare systems. Currently, this arena is very active, and companies are investing significantly in clinical trials of ATMPs post-success of approved products.
Over the past years, several proteins and small molecule-based developing companies have begun focusing on the development of adoptive cell T therapies. For instance, in February 2024, Recipharm, a contract development and manufacturing organization (CDMO), expanded its advanced therapy medicinal products (ATMP’s) offering into virotherapy with the acquisition of Vibalogics.
The tissue-engineered product segment dominated the market attributed to the incorporation of tissue-engineered products or procedures as an integral part of medicine and treatment procedures, particularly in treatments that require functional restoration of any diseased or injured part of the body.
This segment has witnessed significant traction over the past years, as evidenced by the remarkable increase in publications, research studies, clinical trials, and translational products. Furthermore, continuous advancements in technologies and products to advance the tissue engineering process aid in segment growth. For instance, in October 2024, The League of European Research Universities (LERU) announced that two of its members, Lund University, Leiden University Medical Centre (LUMC), along with Skne University Hospital, are joining forces to advance research, education, and development in the field of Advanced Therapy Medicinal Products (ATMPs).
On the other hand, the CAR-T therapy segment is gaining significant momentum in space and is expected to register the fastest CAGR over the forecast period. Key players such as Novartis AG, Gilead Sciences, Inc., and Bristol Myers Squibb are focused on expanding the reach of their CAR-T products across the globe. For instance, Novartis AG announced the approval of its Kymriah by the Health Sciences Authority as Singapore’s first commercially approved CAR-T therapy.
Kymriah is a CAR-T product designed for the treatment of patients with B-cell acute lymphoblastic leukemia and relapsed or refractory (r/r) diffuse large B-cell lymphoma. Similarly, Bristol Myers Squibb’s Breyanzi - a new CAR-T cell therapy for R/R B-Cell Lymphoma secured approval from Japan’s Ministry of Health, Labour, and Welfare (MHLW) in March 2021. This has resulted in a shift in the investment flow toward the development of CAR-T products, leading to significant segment growth.
North America dominated the advanced therapy medicinal products industry and accounted for the largest revenue share of 45.0% in 2024. The increasing number of clinical trials in this new treatment modality in the U.S. supplements regional growth. Also, the favorable environment by regulatory agencies in various countries has introduced frameworks and guidelines to facilitate the development and commercialization of ATMPs. These regulations aim to streamline the approval process and ensure patient safety while encouraging investment and innovation in the field.As of March 2021, the U.S. accounts for around 57.0% of total clinical trials ongoing for gene therapy across the world. This high share indicates the increasing investment flow in this market thereby propelling revenue generation.
Asia Pacific is expected to grow at the fastest CAGR of 21.4%during the forecast period. The region has witnessed a significant increase in healthcare expenditure, leading to greater investment in research and development activities related to advanced therapy medicinal products. This has helped in the development of new and innovative products and technologies, which has boosted market growth. The region has witnessed significant advancements in gene editing technologies, stem cell research, and genetic engineering. Academic institutions, research organizations, and industry players are collaborating to promote research and development in the field of ATMPs, leading to accelerated innovation and market expansion.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the advanced therapy medicinal products market
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers